Curable is a non-profit research accelerator specializing in complex problem solving in rare disease. Curable was originally founded in 2014 as SAVE JON, Inc. and is headquartered in Pittsburgh.
Curable is currently focused on new therapeutic development activity for a rare bile duct and liver disease called primary sclerosing cholangitis (PSC). The majority of PSC patients also have inflammatory bowel disease (IBD), either ulcerative colitis and Crohn's disease. PSC is treated with liver transplantation once the disease progresses to the point of liver failure. Curable has initiated a portfolio of work in the last two years to identify the biologic origins of PSC, focused on areas of interest such as genetics, the microbiome, immune function and the interactions of those systems in the body. Curable also has initiated a number of therapeutic and diagnostic development projects, in collaboration with pharmaceutical and biotech companies, to test new drugs for use in treating PSC, to repurpose existing drugs that might be effective for treating PSC, and to detect PSC earlier and monitor it more closely. Finally, PSC patients are at significantly increased risk for several different types of cancer, and Curable is developing a triage-treatment program to ensure that these rare disease patients facing a new cancer diagnosis get the best available care.
Naomi Herman Phone: (412) 447-0900 email@example.com